Caspian Journal of Internal Medicine
Babol University of Medical Sciences
شنبه 21 شهریور 1405
[Archive]
دوره 17، شماره 3 - ( 4-1405 )
جلد 17 شماره 3 صفحات 689-688 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nazari Taloki Z. Levosimendan in Trastuzumab-Induced Cardiotoxicity: A Mechanism-Based Perspective. Caspian J Intern Med 2026; 17 (3) :688-689
URL: http://caspjim.com/article-1-5081-fa.html
URL: http://caspjim.com/article-1-5081-fa.html
Levosimendan in Trastuzumab-Induced Cardiotoxicity: A Mechanism-Based Perspective. . 1405; 17 (3) :688-689
چکیده: (25 مشاهده)
Trastuzumab is a cornerstone therapy in HER2-positive breast cancer, yet its association with cardiotoxicity remains a major limitation in clinical practice. Trastuzumab-induced cardiac dysfunction, although often considered non-necrotic and potentially reversible, frequently manifests as left ventricular ejection fraction decline and symptomatic heart failure, leading to treatment interruption and compromised oncologic outcomes (1, 2). These clinical challenges highlight the need for a proactive, mechanism-oriented strategy in managing trastuzumab-related cardiac adverse effects.
نوع مطالعه: Letter to Editor |
موضوع مقاله:
Oncology
دریافت: 1404/11/23 | پذیرش: 1405/5/27 | انتشار: 1405/4/8
دریافت: 1404/11/23 | پذیرش: 1405/5/27 | انتشار: 1405/4/8
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
